About the Company
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ICPT News
Intercept Pharmaceuticals stock tumbles toward 11-month low after disappointing FDA committee vote
Shares of Intercept Pharmaceuticals Inc. tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration committee ...
Intercept Pharmaceuticals,
Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver ...
Why Intercept Pharmaceuticals Shares Are Plunging Today
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around 20% after the FDA issued briefing documents ahead of the adcomm meeting scheduled for May 19 to review its liver disease candidate ...
Intercept Pharmaceuticals: Do Not Expect PBC Sales To Save The Company
After last Friday’s unfavorable AdCom meeting, Intercept’s NASH candidate now appears dead on arrival. Some analysts have suggested that Intercept's valuation will be buttressed by their PBC ...
Intercept to go back to FDA with its NASH treatment application
(Reuters) -Intercept Pharmaceuticals Inc will resubmit its application for approval of its therapy for a chronic liver disease to the U.S. Food and Drug Administration, two years after the ...
Intercept Pharma Sued After FDA Sounded Alarm About Drug Deaths
(CN) – Once high-flying biotech firm Intercept Pharmaceuticals faces a derivative action after the company’s share price collapsed when the FDA revealed that 19 patients died after taking its flagship ...
Intercept Pharma Stock Falls as Goldman Cuts to Sell
Shares of Intercept Pharmaceuticals (ICPT) slipped Friday after Goldman Sachs downgraded the biotech firm to sell from neutral and lowered its price target to $10 from $17. Shares of the ...
First Drug to Treat Common, Lethal Liver Disease Gets US Nod
(Bloomberg) -- Madrigal Pharmaceuticals Inc.’s drug Rezdiffra gained the ... Madrigal Stock Triples on Liver Disease Drug Trial Success Intercept Drops as FDA Refuses Speedy Approval of Liver ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ... about our A-beta oligomer target engagement assay from our Phase 1 INTERCEPT-AD study at the international conference on Alzheimer's and Parkinson's ...
Loading the latest forecasts...